Biography
Garo Armen is the Chairman of the Board of MiNK Therapeutics. He is currently the Chairman and Chief Executive Officer of Agenus Inc.
Career
Under his leadership, Agenus has been advancing breakthrough scientific technologies and immunotherapeutic products for more than 20 years. In addition, Garo oversaw the successful restructuring of the biopharmaceutical company Elan Corporation, where he served as Chairman of the Board of Directors. Garo is currently Chairman of the Board of Protagenic Therapeutics, a biotechnology company focusing on human brain hormones for the treatment of neurological and metabolic disorders.
He began his research career at Brookhaven National Laboratory subsequent to which he made a transition to Wall Street, as an analyst and investment banker at EF Hutton and then at Dean Witter Reynolds (now Morgan Stanley), cultivating key relationships and stock-market expertise.
Education
Garo received his Ph.D. in Physical Chemistry from the City University of New York.
Rating GlobalNY.biz
Mentions in the news
Mentioned together
Colleagues
Profile statistic
